Surolan

Surolan is a combination otic suspension manufactured by Elanco (formerly Vetoquinol) that contains three active ingredients working synergistically to treat ear infections: miconazole nitrate (an azole antifungal), polymyxin B sulfate (a polypeptide antibiotic), and prednisolone acetate (a corticosteroid). Unlike many other combination ear medications that are only FDA-approved for dogs and used off-label in cats, Surolan has labeled approval for use in cats in many countries including Canada, the United Kingdom, and throughout Europe, providing veterinarians and cat owners with confidence in its established feline safety profile. This approval status makes Surolan a particularly attractive option for treating feline ear infections when a medication with documented cat-specific safety data is preferred.

The triple-action formulation of Surolan addresses the multiple components typically present in ear infections and provides additional coverage against ear mites. Miconazole nitrate is an azole antifungal that disrupts fungal cell membrane synthesis by inhibiting ergosterol production, making it highly effective against Malassezia pachydermatis yeast as well as dermatophyte fungi such as Microsporum canis and various Trichophyton species. Polymyxin B sulfate is a polypeptide antibiotic with excellent bactericidal activity against gram-negative bacteria including Pseudomonas aeruginosa and Escherichia coli. Prednisolone acetate provides anti-inflammatory and antipruritic effects that reduce swelling, redness, itching, and pain in the ear canal, helping cats feel more comfortable quickly while the antimicrobial components address the underlying infection.

One of Surolan's unique advantages is its documented effectiveness against Otodectes cynotis, the ear mite that causes otoacariasis in cats. Ear mites are an extremely common cause of ear problems in cats, particularly in kittens and cats from multi-cat environments or shelters. Studies have demonstrated Surolan's efficacy in treating ear mite infestations, providing cat owners with a medication that can address both parasitic and microbial causes of ear disease. This dual capability makes Surolan particularly valuable when the exact cause of a cat's ear problem is uncertain, as it covers multiple potential etiologies simultaneously.

Surolan requires twice-daily application, which distinguishes it from some newer once-daily ear medications. While this more frequent dosing schedule requires greater owner commitment, it also provides more frequent medication contact with infected tissues and allows for regular monitoring of treatment response. The medication can also be applied topically to skin for treating localized bacterial and fungal skin infections, providing versatility beyond solely ear applications. Veterinary guidance remains essential for proper diagnosis, appropriate patient selection, and monitoring during treatment to ensure optimal outcomes for feline patients.

Surolan is indicated for the treatment of otitis externa (outer ear canal infections) caused by bacteria, fungi, and yeasts in cats, with the additional indication for treating ear mite infestations caused by Otodectes cynotis. The medication effectively targets a broad range of pathogens including gram-negative bacteria such as Pseudomonas aeruginosa and Escherichia coli (covered by polymyxin B), gram-positive bacteria including Staphylococcus species (miconazole has some antibacterial activity against gram-positive organisms), yeasts particularly Malassezia pachydermatis, and dermatophyte fungi. This comprehensive antimicrobial and antiparasitic spectrum makes Surolan suitable for treating the diverse causes of feline ear infections.

The indication for ear mite treatment represents a significant advantage of Surolan in feline medicine. Otodectes cynotis ear mites are among the most common causes of ear problems in cats, particularly affecting kittens and cats from shelters or multi-cat households. Cats with ear mites typically present with dark, coffee-ground-like ear debris, intense ear itching, and head shaking. Surolan's documented efficacy against ear mites, combined with its antibacterial and antifungal activity, makes it an excellent choice when ear mites are confirmed or suspected, as secondary bacterial or yeast infections frequently accompany mite infestations.

Surolan's antifungal component miconazole provides excellent coverage against Malassezia pachydermatis, the yeast most commonly isolated from infected feline ear canals. Yeast overgrowth in the ear can occur as a primary problem or secondary to other ear conditions including allergies, bacterial infection, or ear mites. The medication's ability to address yeast infections while simultaneously treating potential bacterial co-infections and reducing inflammation makes it effective for the mixed etiology ear infections commonly encountered in clinical practice.

Beyond ear infections, Surolan is also indicated for topical treatment of localized skin infections (dermatitis) in cats caused by susceptible bacteria and fungi. Skin conditions including hot spots, localized pyoderma, and fungal skin infections may be treated with Surolan applied directly to the affected skin areas. This dual otic and dermal indication provides versatility, though separate products may be preferred if large skin areas require treatment. The medication should be applied topically to affected skin areas twice daily after clipping hair from around the affected area.

Veterinarians may select Surolan based on its labeled approval for cats in many regions, its effectiveness against ear mites, its antifungal and antibacterial coverage, or specific patient factors. The polymyxin B antibiotic provides an alternative to aminoglycoside antibiotics found in many other ear medications, which may be preferred in certain clinical situations. When ear cytology reveals a mixed population of bacteria and yeast, or when ear mites are identified, Surolan represents an excellent empirical choice that addresses multiple potential causes simultaneously.

The dosing of Surolan in cats follows the label directions for feline patients in regions where the product is approved for cat use, or veterinarian-specific instructions in areas where it may be used off-label. The standard dose for treating feline otitis externa involves instilling three to five drops of Surolan into each affected ear canal twice daily. The exact number of drops may be adjusted based on the cat's size and the severity of infection, with smaller cats or less severe infections potentially receiving fewer drops. Treatment is typically continued for five to seven days minimum, or until the infection has resolved as confirmed by veterinary examination.

Proper administration technique is essential for effective treatment and begins with preparing the medication and the cat. Shake the Surolan bottle well before each use to ensure uniform suspension of the active ingredients. Gently restrain the cat in a comfortable position, ideally with assistance from another person if the cat is uncooperative or anxious. Lift the ear flap (pinna) to straighten the ear canal and visualize the opening. Position the bottle tip just above the ear canal without inserting it deeply, and gently squeeze to instill the prescribed number of drops. After application, fold the ear flap down and gently massage the base of the ear for approximately thirty seconds to distribute the medication throughout the ear canal.

For ear mite treatment, Surolan should be applied twice daily for approximately three weeks to ensure elimination of all life stages of the mites. Ear mites have a three-week life cycle, and continuing treatment for this duration helps ensure that newly hatched mites are killed before they can reproduce. Some veterinarians may recommend treating all cats in a multi-cat household simultaneously, even if only one cat shows clinical signs, to prevent reinfestation from asymptomatic carriers. Follow-up examination to confirm mite elimination is recommended at the end of the treatment course.

Before beginning Surolan treatment, the veterinarian typically recommends cleaning the ear canal to remove accumulated debris, mite waste products, discharge, and wax that could interfere with medication penetration. For ear mite cases, the dark debris characteristic of mite infestation should be gently cleaned before initiating treatment. Ear cleaning should be performed using a veterinarian-approved cleaner appropriate for cats. During active treatment, additional cleaning may be recommended periodically, particularly for ear mite cases where debris accumulation can be substantial.

If a dose of Surolan is missed, apply it as soon as remembered and then continue with the regular twice-daily schedule. If the missed dose is not remembered until almost time for the next scheduled dose, skip the missed dose and continue with the normal schedule. Never apply a double dose to make up for missed applications. Consistent twice-daily application at approximately the same times each day (typically morning and evening, approximately twelve hours apart) helps maintain therapeutic medication levels in the ear canal and establishes a routine that may improve treatment compliance.

For topical skin application, the affected area should be clipped of hair and cleaned before applying Surolan. Sufficient drops are applied to cover the affected area, and the medication is rubbed in gently. Treatment is continued twice daily until the infection has resolved. Cats should be prevented from licking treated skin areas; an Elizabethan collar may be necessary to prevent oral ingestion of the medication.

Surolan is generally well-tolerated in cats when used as directed, with the medication's approved status for feline use in many regions reflecting its established safety profile. Most cats complete treatment without experiencing significant adverse effects. The combination of miconazole, polymyxin B, and prednisolone has been used in veterinary medicine for many years, providing extensive clinical experience with its tolerability in feline patients. However, as with any medication, side effects can occur, and cat owners should be aware of potential reactions to monitor during treatment.

Local reactions at the site of application represent the most commonly reported side effects in cats receiving Surolan. Some cats may experience temporary discomfort, mild stinging, or irritation when the medication is first applied, particularly if the ear canal is severely inflamed or ulcerated. This initial discomfort typically subsides within a few minutes and often becomes less pronounced with subsequent applications as the ear begins to heal. If irritation appears to worsen progressively rather than improve during treatment, veterinary evaluation is recommended to assess for potential allergic reaction or need for treatment modification.

Allergic reactions to components of Surolan can occur in sensitive cats, though they are relatively uncommon. Signs of allergic reaction may include increased redness and swelling of the ear or surrounding tissues, development of hives or skin irritation around the treated area, and intensified scratching or head shaking that worsens rather than improves with treatment. Cats with known hypersensitivity to miconazole, polymyxin B, prednisolone, or related compounds should not receive Surolan. Any suspected allergic reaction should prompt discontinuation of the medication and veterinary consultation.

Potential ototoxicity (damage to hearing or balance structures) is a consideration with any ear medication, though polymyxin B is generally considered to have lower ototoxicity risk than aminoglycoside antibiotics found in some alternative products. However, if Surolan penetrates through a ruptured tympanic membrane into the middle or inner ear, damage to delicate structures could potentially occur. Signs of possible ototoxicity include hearing changes, head tilt, loss of balance, circling, nystagmus (involuntary eye movements), and incoordination. Proper otoscopic examination to verify eardrum integrity before prescribing Surolan significantly reduces this risk.

Systemic absorption of the prednisolone corticosteroid component can occur, particularly with prolonged or extensive use. While amounts absorbed from topical otic application are generally small, cats receiving extended treatment courses or those also receiving systemic corticosteroids should be monitored for signs of excessive corticosteroid effects including increased thirst and urination, increased appetite, behavioral changes, or skin changes. The product labeling notes that long-term use of topical corticosteroids has been associated with adrenocortical suppression. Surolan is intended for short-term treatment, and extended or repeated courses should involve regular veterinary monitoring.

Surolan is contraindicated in cats with known hypersensitivity to any of its active ingredients, including miconazole nitrate, polymyxin B sulfate, or prednisolone acetate. Cats that have previously experienced allergic reactions to azole antifungals, polymyxin antibiotics, or corticosteroids should not receive Surolan without careful veterinary evaluation of risks versus benefits. If hypersensitivity to any component develops during treatment, as indicated by worsening irritation, swelling, or rash, the medication should be discontinued.

The presence of a perforated or ruptured tympanic membrane (eardrum) is a contraindication for Surolan use, as stated in the product labeling. When the eardrum is not intact, medication can penetrate into the middle and inner ear, potentially causing damage to delicate structures responsible for hearing and balance. Before prescribing Surolan, veterinarians should examine the ear with an otoscope to visualize the eardrum and confirm its integrity. If severe swelling, debris, or discharge prevents adequate visualization of the eardrum, the veterinarian may recommend treatment to reduce inflammation or ear cleaning before Surolan can be safely initiated.

Pregnant and lactating cats require careful consideration before Surolan use, as the product labeling indicates that safe use in animals used for breeding purposes, during pregnancy, or in lactating animals has not been evaluated. Corticosteroids such as prednisolone have known potential effects on fetal development when administered systemically, and while topical otic application results in limited systemic absorption, theoretical risks exist. Veterinarians should discuss these considerations with owners of pregnant or nursing cats and may recommend alternative treatments with better-established reproductive safety profiles if available.

Caution is advised when applying Surolan to extensive body surface areas, as increased systemic absorption of the corticosteroid component can occur. If large areas require treatment, alternative approaches may be more appropriate, and careful monitoring for systemic corticosteroid effects is warranted. Similarly, if excessive oral ingestion by the cat is likely due to grooming behavior, preventive measures such as an Elizabethan collar should be employed, or alternative treatments considered. Cats with known liver disease may require additional caution, as systemic corticosteroid effects could potentially be enhanced if hepatic metabolism is impaired.

Concurrent use of Surolan with other otic medications should generally be avoided unless specifically directed by a veterinarian. Combining multiple ear treatments can lead to unpredictable interactions, altered efficacy, or increased risk of adverse reactions including local irritation. The vehicle and formulation of different otic products may not be compatible when combined in the ear canal. If a cat's ear infection requires a therapeutic approach not fully addressed by Surolan alone, the veterinarian will provide specific guidance on timing and administration of multiple products or select an alternative single product with appropriate coverage.

The polymyxin B component of Surolan may have additive or synergistic effects with other antibiotics affecting gram-negative bacteria. While this is generally considered beneficial when combating resistant infections, concurrent use of multiple antibiotics should be under veterinary direction to ensure appropriate antimicrobial stewardship and monitoring for adverse effects. The miconazole antifungal component has been shown to have synergistic antimicrobial effects with polymyxin B against certain organisms, which is part of the rationale for their combination in Surolan.

The prednisolone corticosteroid in Surolan may contribute to cumulative corticosteroid effects in cats receiving concurrent systemic or topical corticosteroid therapy. Cats being treated with oral prednisolone, injectable corticosteroids such as methylprednisolone or dexamethasone, topical steroid creams, or corticosteroid-containing eye medications may experience enhanced corticosteroid effects when Surolan is added. Signs of excessive corticosteroid exposure can include increased thirst and urination, increased appetite, behavioral changes, and with prolonged exposure, potential adrenal suppression or iatrogenic hyperadrenocorticism. Complete medication disclosure to the veterinarian enables appropriate assessment of total corticosteroid load.

Ear cleaners should be used as directed by the veterinarian in relation to Surolan application. Some ear cleaners are compatible with concurrent use during treatment, while others may interfere with medication action if used too frequently or at inappropriate times. Generally, if ear cleaning is needed during treatment, it should be performed several hours before Surolan application to allow the ear to dry and prevent dilution of the medication. Owners should not use any ear products other than those specifically recommended by the treating veterinarian.

Veterinary examination and proper diagnosis should always precede Surolan use to ensure appropriate treatment selection and patient safety. Ear problems in cats can result from various causes including bacterial infection, yeast overgrowth, ear mites, foreign bodies, inflammatory polyps, or tumors, each potentially requiring different treatment approaches. Ear cytology helps identify organisms present and guides medication selection, while otoscopic examination evaluates ear canal condition and tympanic membrane integrity. The product labeling specifically recommends examining the external ear canal to confirm the tympanic membrane is not ruptured before instilling medication.

If overgrowth of non-susceptible bacteria or fungi occurs during Surolan treatment, the medication should be discontinued and appropriate alternative therapy instituted. Signs that might indicate treatment failure or emergence of resistant organisms include persistent or worsening symptoms despite appropriate treatment duration, change in the character of ear discharge, or development of new symptoms. Veterinary re-evaluation is warranted if the ear infection does not show improvement within several days of initiating treatment or if it worsens at any point.

Care should be exercised to avoid excessive oral ingestion of Surolan when applying the medication to extensive skin areas or ears of cats who groom frequently. While small amounts incidentally ingested during normal grooming are unlikely to cause problems, significant oral ingestion could potentially lead to systemic effects from the corticosteroid component or gastrointestinal upset. Elizabethan collars may be necessary for cats who persistently attempt to lick treated areas. Monitoring for signs of systemic corticosteroid effects is advisable when treatment is extensive or prolonged.

Some canine and feline fungal infections treated with Surolan are transmissible to humans, as noted in the product labeling. Cat owners treating ear infections or skin infections caused by dermatophyte fungi (ringworm) should take appropriate precautions including washing hands after handling the cat or applying medication, avoiding contact between the infected area and broken skin, and monitoring household members for signs of infection. Immunocompromised individuals should take particular care when handling cats with fungal infections.

The product labeling indicates that safe use in animals used for breeding purposes, during pregnancy, or in lactating animals has not been evaluated. Veterinarians and cat owners should consider these limitations when treating breeding cats. Additionally, in multi-cat households with ear mite infestations, all cats should typically be examined and potentially treated to prevent reinfestation from untreated carriers, even if only one cat shows clinical symptoms.

Surolan should be stored at controlled room temperature between fifty-nine and seventy-seven degrees Fahrenheit (fifteen to twenty-five degrees Celsius), protected from excessive heat, cold, and direct sunlight. The medication should not be frozen, as this can affect the stability and consistency of the suspension. Proper storage maintains the medication's effectiveness and appropriate texture throughout its shelf life. The product should be kept in its original bottle with the cap tightly closed when not in use to prevent contamination and evaporation.

Before each use, the Surolan bottle should be shaken well and rolled between the hands to ensure uniform suspension of the active ingredients and proper mixing of the formulation. The medication contains particles that settle between applications, and failure to shake the bottle adequately can result in inconsistent dosing with some applications containing different concentrations of active ingredients. The suspension should appear uniformly mixed after shaking; if the product appears unusual, separated, or fails to mix properly despite thorough agitation, it should not be used and should be shown to the veterinarian or pharmacist.

The bottle tip should remain clean and should not contact the cat's ear, skin, or other surfaces during application to prevent contamination of the remaining medication. Position the tip above the ear canal and allow drops to fall into the canal without direct contact. If the tip inadvertently contacts the ear during application, wipe it clean with a tissue before replacing the cap. Each bottle of Surolan should be used for only one patient to prevent cross-contamination between pets, even in multi-cat households where multiple cats may have ear infections.

Proper disposal of expired or unused Surolan should follow local pharmaceutical waste guidelines. The medication should not be flushed down toilets or poured down drains due to environmental concerns about pharmaceutical contamination of water systems. Many veterinary clinics and pharmacies offer take-back programs for proper pharmaceutical disposal. Throughout storage and use, Surolan should be kept out of reach of children and other household pets to prevent accidental exposure. The product is for external use only and should never be administered orally.

Surolan can be used in cats of all breeds when appropriately prescribed by a veterinarian, with the medication demonstrating consistent effectiveness against common ear pathogens and ear mites regardless of breed background. The approved status for feline use in many regions provides confidence in its safety across diverse cat populations. However, awareness of breed-specific characteristics may influence treatment decisions, administration technique, or monitoring requirements for individual patients.

Cat breeds with distinctive ear conformations may present unique considerations during treatment. Scottish Fold cats have altered external ear anatomy due to their folded cartilage, which can affect medication distribution and potentially predispose them to ear infections from trapped moisture and debris. Surolan can be used in Scottish Folds, but owners and veterinarians should ensure adequate medication penetration into the ear canal despite the folded structure. American Curl cats with backward-curling ears may similarly require modified handling during treatment. Persian cats and brachycephalic breeds may have altered ear canal anatomy predisposing them to chronic ear problems.

Breeds prone to ear mite infestations may particularly benefit from Surolan's documented efficacy against Otodectes cynotis. While ear mites can affect any cat, they are particularly common in cats from shelters, multi-cat environments, or outdoor settings. Mixed-breed cats from these backgrounds frequently present with ear mite infestations. Surolan's ability to address ear mites while simultaneously treating secondary bacterial and yeast infections makes it especially valuable for these patients. Purebred cats acquired from catteries may also have mite exposure if the source facility was affected.

White cats, particularly those with blue eyes, may have congenital deafness related to coat color genetics. These cats have inner ear abnormalities present from birth that are unrelated to medication exposure. While using Surolan in a congenitally deaf cat would not cause additional hearing damage to already-affected structures, veterinarians should discuss the cat's hearing status with owners. For any cat with known or suspected hearing impairment from any cause, verifying eardrum integrity before treatment and monitoring for any vestibular effects during treatment remains important, regardless of breed.

Long-haired breeds including Persians, Maine Coons, and Ragdolls may require additional attention to hair removal around the ear canal before Surolan application to ensure optimal medication penetration. Hair can act as a wick, drawing medication away from the ear canal, or can become matted with discharge and debris, creating a barrier to treatment. The product labeling recommends clipping excessive hair away from treatment areas for skin applications, and this principle can be extended to ear treatment in very hairy cats.

Mometamax (gentamicin, mometasone, and clotrimazole) offers once-daily dosing compared to Surolan's twice-daily application but uses an aminoglycoside antibiotic (gentamicin) rather than polymyxin B. The gentamicin provides excellent Pseudomonas coverage and broader gram-positive activity than polymyxin B but carries higher ototoxicity risk. Mometamax is commonly used off-label in cats for ear infections, particularly those involving Pseudomonas. The choice between Surolan and Mometamax may depend on suspected organisms, dosing convenience preferences, ototoxicity concerns, and whether labeled cat approval (where Surolan is approved) is important to the veterinarian or owner.

Posatex (orbifloxacin, posaconazole, and mometasone) provides an alternative combination with a fluoroquinolone antibiotic, which offers a different mechanism of antibacterial action and is considered to have lower ototoxicity risk than aminoglycosides. Posatex requires once-daily application and is used off-label in cats. The fluoroquinolone's broad-spectrum coverage including excellent Pseudomonas activity makes Posatex attractive for challenging bacterial infections. However, Posatex lacks the ear mite activity that Surolan provides, which may influence selection when parasitic etiology is suspected.

Otomax (gentamicin, betamethasone, and clotrimazole) is similar to Mometamax, using the same gentamicin antibiotic but with betamethasone corticosteroid and requiring twice-daily application. Otomax has been available for decades and has extensive clinical experience in both dogs and cats (off-label). The ointment formulation differs from Surolan's liquid suspension. Like Surolan, Otomax requires twice-daily dosing, so convenience differences are minimal, but the antibiotic coverage and ototoxicity profile differ between the products.

Tresaderm (thiabendazole, dexamethasone, and neomycin) is FDA-approved for both dogs and cats in the United States, providing labeled feline use like Surolan has in other regions. Tresaderm requires twice-daily application and refrigeration. The thiabendazole component provides antifungal and some antiparasitic activity, though dedicated ear mite treatments may be more reliable for confirmed infestations. Neomycin provides narrower antibacterial coverage than polymyxin B for gram-negative organisms. Tresaderm remains a viable option when a US-labeled feline ear medication is preferred, though its antimicrobial spectrum differs from Surolan's.